{"id":1429,"date":"2010-02-09T19:45:06","date_gmt":"2010-02-10T00:45:06","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/tuesday-february-9-news-roundup-rosuvastatin-gets-primary-prevention-indication-providing-global-risk-assessment-ibd-vte\/"},"modified":"2011-07-19T17:45:04","modified_gmt":"2011-07-19T21:45:04","slug":"tuesday-february-9-news-roundup-rosuvastatin-gets-primary-prevention-indication-providing-global-risk-assessment-ibd-vte","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/02\/09\/tuesday-february-9-news-roundup-rosuvastatin-gets-primary-prevention-indication-providing-global-risk-assessment-ibd-vte\/","title":{"rendered":"Tuesday February 9 News Roundup: Rosuvastatin Gets Primary Prevention Indication; Providing Global Risk Assessment; IBD &amp; VTE"},"content":{"rendered":"<p><strong>New Indication for Crestor:<\/strong> The FDA on Monday granted a primary prevention indication for rosuvastatin (Crestor, AstraZeneca). The decisionis based on the results of the JUPITER trial and a subsequent FDA advisory panel hearing. Click <a href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm199891.htm\">here to read the FDA\u2019s&nbsp;Questions and Answers from the FDA for Healthcare Professionals on CRESTOR and the JUPITER Trial<\/a>. Click here to <a href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021366s016lbl.pdf\">download&nbsp;a PDF of the new label<\/a>.<\/p>\n<p><strong>Global Risk:<\/strong> Providing patients with a global coronary heart disease risk estimation helps &#8220;improve the accuracy of risk perception and may increase intent to initiate CHD prevention among individuals at moderate to high risk,&#8221; according &nbsp;to <a href=\"http:\/\/archinte.ama-assn.org\/cgi\/content\/short\/170\/3\/230?home\">a systematic review by Sheridan and colleagues <\/a>in <em>Archives of Internal Medicine<\/em>, but evidence remains elusive that this information actually benefits the patients.&nbsp;Although we &#8220;need to shift from a reactive to a preventive paradigm in&nbsp;medicine,&#8221; write&nbsp;Tariq Ahmad and Samia Mora in <a href=\"http:\/\/archinte.ama-assn.org\/cgi\/content\/full\/170\/3\/227\">an accompanying editorial<\/a>, &#8220;the role of risk&nbsp;scores in this shift, and the newer biomarker and genetic information&nbsp;relating to personalized medicine, remain to be determined.&#8221;<\/p>\n<p><strong>IBD &amp; VTE: <\/strong>Non-hospitalized patients who have active inflammatory bowel disease are 16 times more likely to develop VTE than controls, according to<a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(09)61963-2\/fulltext?_eventId=login\"> a new study from the UK General Practice Research Database appearing in the <em>Lancet<\/em>.<\/a>&nbsp;In their conclusion the authors say that &#8220;trials of primary prophylaxis of venous thromboembolism are warranted&#8221; in this population.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Indication for Crestor: The FDA on Monday granted a primary prevention indication for rosuvastatin (Crestor, AstraZeneca). The decisionis based on the results of the JUPITER trial and a subsequent FDA advisory panel hearing. Click here to read the FDA\u2019s&nbsp;Questions and Answers from the FDA for Healthcare Professionals on CRESTOR and the JUPITER Trial. Click [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1429","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1429"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1429\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}